Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612540 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL242797 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL26722446 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL12699779 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL4189941 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL90804 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL8825950 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL13447 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL166482 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL14621027 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262233-A1 | SYNTHESIS OF PREFFERED ISOMER FRACTIONS OF N, N-DIETHYLDECAHYDROQUINOLINIUM CATION | CHEVRON U.S.A. INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008048858-A2 | SYNTHESIS OF PREFERRED ISOMER FRACTIONS OF N,N-DIETHYLDECAHYDROQUINOLINIUM CATION | CHEVRON U.S.A. INC. (US) | 2008-04-24 | — | — | WO | claimed |
| CN-107628998-B | Preparation method of lepadin alkaloid synthetic intermediate | 四川大学 | 2021-01-15 | — | — | CN | disclosed |
| CN-107628998-B | Preparation method of lepadin alkaloid synthetic intermediate | 四川大学 | 2021-01-15 | — | — | CN | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| CN-106458825-A | Novel method for producing 1,3-di-substituted-cyclobutane-1,2,3,4-tetracarboxylic acid and dianhydride of said acid | 日产化学工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-2283004-B1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-05-27 | — | — | EP | disclosed |
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-8614209-B2 | Amido-thiophene compounds and their use | THE UNIVERSITY OF EDINBURGH (GB) | 2013-12-24 | — | — | US | disclosed |
| US-8592452-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-5916899-A | SOLID PHASE SYNTHESIS, REACTING PROTECTED AMINO ACID WITH SOLID SUPPORT; FORMING IMINE BY REACTION WITH ALDEHYDE, CYCLIZATION WITH ANHYDRIDE, CLEAVAGE AND DEPROTECTION. | TREGA BIOSCIENCES, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| CN-1202888-A | Isoquinoline derivatives and isoquinoline combinatorial libraries | TORREY PINES INST (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-3941579-A | Regulating the growth of plants and controlling weeds with carbonyl-substituted azabicycloalkanes | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | MBTD1 2128/4885L3MBTL3 3157/4885EPAS1 818/4885 |
| US-20080262233-A1 | SYNTHESIS OF PREFFERED ISOMER FRACTIONS OF N, N-DIETHYLDECAHYDROQUINOLINIUM CATION | DDAH1, HCN2, HCN1 | MBTD1 3920/4885L3MBTL3 4192/4885EPAS1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.